drug_type
RELEVANT_DRUG
intervention_type
Biologic (monoclonal antibody immunotherapy)
drug_description
Humanized IgG1 monoclonal antibody targeting CD117 (c-KIT) on hematopoietic stem and progenitor cells; blocks SCF-c-KIT signaling to deplete CD117+ cells. Administered IV on Day 1 of each 8-week cycle for up to 4 cycles.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Monoclonal, Humanized
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized IgG1 monoclonal antibody targeting CD117 (c-KIT) on hematopoietic stem and progenitor cells; blocks stem cell factor (SCF)–c-KIT signaling to suppress survival/maintenance and deplete CD117+ cells (including malignant clones), with depletion aided by Fc-mediated effector functions such as ADCC/phagocytosis.
drug_name
Briquilimab (JSP191)
nct_id_drug_ref
NCT05903274